A Banner Year for Biosimilars: The 19 FDA Approvals From 2024

January 21, 2025

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.

BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars

January 20, 2025

FTC Releases Second Report on PBMs Meddling in Generic Drug Markets

January 19, 2025

Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease

January 18, 2025

The Top 5 Biosimilar Articles for the Week of January 13

January 17, 2025

The Top 5 Biosimilar Articles for the Week of December 16

December 20th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 16, 2024.

China's Biosimilar Market: Trastuzumab Uptake and Future Trends

December 19th 2024

By Cameron Santoro

Article

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing market share and reducing costs despite initial barriers.

FDA Approves Steqeyma: The Seventh Stelara Biosimilar

December 18th 2024

By Skylar Jeremias

Article

The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025.

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

December 18th 2024

By Skylar Jeremias

Article

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.

13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching

December 18th 2024

By Skylar Jeremias

Article

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.

Study Shows Biosimilarity of Bevacizumab Biosimilar in CRC

December 17th 2024

By Skylar Jeremias

Article

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) in patients with metastatic colorectal cancer (CRC).

Health Canada Approves First Omalizumab Biosimilar

December 16th 2024

By Skylar Jeremias

Article

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.

Strategies for Improving Biosimilar Access and Utilization

December 15th 2024

By Skylar Jeremias

Video

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discussed barriers to biosimilar adoption and highlighted strategies such as physician education, streamlined implementation, payer collaboration, and patient engagement to improve access, reduce costs, and enhance adherence to biologic therapies.

Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17

December 14th 2024

By Deana Ferreri, PhD

Article

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.

Trastuzumab’s Evergreening Impact on Biosimilars, Health Care Costs

December 13th 2024

By Cameron Santoro

Article

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands led to significant price reductions and increased market share.